Precision BioSciences Inc
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalent… Read more
Precision BioSciences Inc (DTIL) - Net Assets
Latest net assets as of September 2025: $16.63 Million USD
Based on the latest financial reports, Precision BioSciences Inc (DTIL) has net assets worth $16.63 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($93.51 Million) and total liabilities ($76.88 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $16.63 Million |
| % of Total Assets | 17.79% |
| Annual Growth Rate | N/A |
| 5-Year Change | 26.94% |
| 10-Year Change | N/A |
| Growth Volatility | 127.58 |
Precision BioSciences Inc - Net Assets Trend (2016–2024)
This chart illustrates how Precision BioSciences Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Precision BioSciences Inc (2016–2024)
The table below shows the annual net assets of Precision BioSciences Inc from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $56.39 Million | +198.99% |
| 2023-12-31 | $18.86 Million | -68.79% |
| 2022-12-31 | $60.43 Million | -33.71% |
| 2021-12-31 | $91.17 Million | +105.22% |
| 2020-12-31 | $44.42 Million | -67.88% |
| 2019-12-31 | $138.31 Million | +246.13% |
| 2018-12-31 | $39.96 Million | +251.54% |
| 2017-12-31 | $-26.37 Million | -455.25% |
| 2016-12-31 | $-4.75 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Precision BioSciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 46445500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Components | $538.86 Million | 955.54% |
| Total Equity | $56.39 Million | 100.00% |
Precision BioSciences Inc Competitors by Market Cap
The table below lists competitors of Precision BioSciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
OFX Group Ltd
AU:OFX
|
$70.52 Million |
|
Aurion Resources Ltd
OTCQX:AIRRF
|
$70.55 Million |
|
Value Valves Co Ltd
TWO:4580
|
$70.55 Million |
|
Skue Sparebank
OL:SKUE
|
$70.56 Million |
|
Apetit Oyj
HE:APETIT
|
$70.45 Million |
|
Sebang Co Ltd
KO:004365
|
$70.43 Million |
|
Sound Financial Bancorp Inc
NASDAQ:SFBC
|
$70.40 Million |
|
Digital Daesung Co. Ltd
KQ:068930
|
$70.39 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Precision BioSciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 18,861,000 to 56,393,000, a change of 37,532,000 (199.0%).
- Net income of 7,167,000 contributed positively to equity growth.
- New share issuances of 50,238,000 increased equity.
- Other factors decreased equity by 19,873,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $7.17 Million | +12.71% |
| Share Issuances | $50.24 Million | +89.09% |
| Other Changes | $-19.87 Million | -35.24% |
| Total Change | $- | 198.99% |
Book Value vs Market Value Analysis
This analysis compares Precision BioSciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.85x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-0.28 | $6.93 | x |
| 2017-12-31 | $-23.51 | $6.93 | x |
| 2018-12-31 | $24.45 | $6.93 | x |
| 2019-12-31 | $98.80 | $6.93 | x |
| 2020-12-31 | $25.61 | $6.93 | x |
| 2021-12-31 | $46.60 | $6.93 | x |
| 2022-12-31 | $20.63 | $6.93 | x |
| 2023-12-31 | $4.91 | $6.93 | x |
| 2024-12-31 | $8.19 | $6.93 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Precision BioSciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.71%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.43%
- • Asset Turnover: 0.50x
- • Equity Multiplier: 2.42x
- Recent ROE (12.71%) is above the historical average (-106.49%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | -117.62% | 0.07x | 0.00x | $-7.78 Million |
| 2017 | 0.00% | -325.45% | 0.09x | 0.00x | $-18.47 Million |
| 2018 | -115.21% | -423.02% | 0.08x | 3.47x | $-50.03 Million |
| 2019 | -67.15% | -417.65% | 0.09x | 1.70x | $-106.71 Million |
| 2020 | -245.37% | -448.86% | 0.16x | 3.38x | $-113.45 Million |
| 2021 | -33.57% | -26.49% | 0.55x | 2.32x | $-39.72 Million |
| 2022 | -184.73% | -444.80% | 0.11x | 3.94x | $-117.68 Million |
| 2023 | -325.11% | -125.84% | 0.30x | 8.47x | $-63.21 Million |
| 2024 | 12.71% | 10.43% | 0.50x | 2.42x | $1.53 Million |
Industry Comparison
This section compares Precision BioSciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Precision BioSciences Inc (DTIL) | $16.63 Million | 0.00% | 4.62x | $70.50 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |